MSCs can alter the anti-tumor immune response and enable tumor progression through expression of immunomodulatory ligands, such as programmed death-ligand 1 (PD-L1), PD-L2, and Fas ligand [17,65]. This evidence concerns the gene PDCD1LG2 and neoplasm.